DaVita CEO: ESRD Reg Likely Won't Make Short List For Congressional Review Act

January 11, 2017
Davita CEO Ken Thiry told Inside Health Policy that the company has asked Congress to overturn CMS' interim final rule requiring dialysis facilities' get issuer approval before helping a patient with premium assistance, but said the rule is unlikely to make the short list of measures the GOP will try to ax though the Congressional Review Act. On Jan. 6, DaVita, Fresenius, and U.S Renal Care joined Dialysis Patient Citizens in asking a federal court to issue a temporary...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.